You are leaving our website

or Decline

Alliance Pharmaceuticals Limited Completes Sale of Pharmaceutical Division

Alliance Pharmaceuticals Limited (“Alliance”) entered into a definitive agreement to sell its pharmaceutical division to two unrelated UK pharmaceutical companies. The transaction completed on 7th January 2026. This outcome follows a comprehensive strategic review and is aligned with Alliance’s strategy to become a leading consumer health business. Alliance looks forward to working with the acquiring companies to support a successful separation.

Realising potential

Brands achieve more with Alliance.

Our alliances allow us to unlock potential. We maximise the performance of every business and every brand.

Help your scar fade to feel your confidence grow.

KELO-COTE™ is an advanced formula silicone treatment which helps improve the appearance of hypertrophic and keloid scars and helps prevent them from forming.

Kelo-Cote™

Nizoral™ a medicated anti-dandruff shampoo.

Nizoral™ kills the fungus that can cause itchy, flaky scalps and dandruff. Alliance’s association with the NIZORAL™ Shampoo brand is only applicable to APAC territories.

Nizoral™
Our Brands

Building alliances

Partners achieve more with Alliance.

Building new partnerships enables us to achieve things that otherwise wouldn’t be possible.

Our strategy

Achieving more

How we delivered for our shareholders in 2024

> Expanded gross margin. Increased investment behind our key brands
> Maintained underlying group profit
> Strengthened the skills, experience and expertise on the Executive Committee to align with the long term strategy
> Commenced work to adapt the Company's culture and capabilities to support our ambition to become a high-performing Consumer Healthcare Company
> Good progress made with developing and executing our sustainability strategy